Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|September 30, 2025
Classifying hypopneas as obstructive or central can enhance transvenous phrenic nerve stimulation therapy patient selection and outcomesKara Dupuy-McCauley, Alan R Schwartz, Shahrokh Javaheri, et al.
Archives of Dermatological Research|April 15, 2004
Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and armsLester I Harrison, Shari L Skinner, Thomas C Marbury, et al.
Sleep|March 28, 2025
Determinants of Transvenous Phrenic Nerve Stimulation-Induced Improvements in LV Function in Central Sleep Apnea and Heart FailureAli Azarbarzin, Neda Esmaeili, Daniel Vena, et al.
Sleep & Breathing = Schlaf & Atmung|September 26, 2025
Real world characteristics of central sleep apnea: a review of 29,000 consecutive patients undergoing polysomnographySanjay R Patel, Michael V Genuardi, Rebecca DeSensi, et al.
ESC Heart Failure|October 18, 2024
Win ratio analysis of transvenous phrenic nerve stimulation to treat central sleep apnoea in heart failureWilliam T Abraham, Olaf Oldenburg, Mitja Lainscak, et al.
Sleep Medicine|October 15, 2024
Multidimensional phenotyping to distinguish among central (CSA), obstructive (OSA) and co-existing central and obstructive sleep apnea (CSA-OSA) phenotypes in real-world dataJean-Louis Pépin, Alan R Schwartz, Rami Khayat, et al.
Cancer Chemotherapy and Pharmacology|December 12, 2012
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumorsMichael S Gordon, Robert Ilaria, Dinesh P de Alwis, et al.
Heart Rhythm|July 4, 2020
Transvenous phrenic nerve stimulation for central sleep apnea is safe and effective in patients with concomitant cardiac devicesHemal M Nayak, Raj Patel, Scott McKane, et al.
Investigational New Drugs|April 12, 2012
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancerGlen J Weiss, Ross C Donehower, Tara Iyengar, et al.
Sleep|October 22, 2019
Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apneaHenrik Fox, Olaf Oldenburg, Shahrokh Javaheri, et al.
Pageof 3